197 related articles for article (PubMed ID: 32733026)
21. Mutant TP53 G245C and R273H promote cellular malignancy in esophageal squamous cell carcinoma.
Kang N; Wang Y; Guo S; Ou Y; Wang G; Chen J; Li D; Zhan Q
BMC Cell Biol; 2018 Aug; 19(1):16. PubMed ID: 30126368
[TBL] [Abstract][Full Text] [Related]
22. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.
Ahronian LG; Zhu LJ; Chen YW; Chu HC; Klimstra DS; Lewis BC
Oncogene; 2016 Sep; 35(35):4653-62. PubMed ID: 26876204
[TBL] [Abstract][Full Text] [Related]
23. KLF6 inhibited oral cancer migration and invasion via downregulation of mesenchymal markers and inhibition of MMP-9 activities.
Hsu LS; Huang RH; Lai HW; Hsu HT; Sung WW; Hsieh MJ; Wu CY; Lin YM; Chen MK; Lo YS; Chen CJ
Int J Med Sci; 2017; 14(6):530-535. PubMed ID: 28638268
[TBL] [Abstract][Full Text] [Related]
24. GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.
Lin F; Xie YJ; Zhang XK; Huang TJ; Xu HF; Mei Y; Liang H; Hu H; Lin ST; Luo FF; Lang YH; Peng LX; Qian CN; Huang BJ
J Exp Clin Cancer Res; 2019 Apr; 38(1):152. PubMed ID: 30961661
[TBL] [Abstract][Full Text] [Related]
25. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma.
Babu D; Chintal R; Panigrahi M; Phanithi PB
Cell Oncol (Dordr); 2022 Dec; 45(6):1451-1465. PubMed ID: 36284039
[TBL] [Abstract][Full Text] [Related]
26. Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma.
Kong LM; Yao L; Lu N; Dong YL; Zhang J; Wang YQ; Liu L; Zhang HL; Huang JG; Liao CG
Oncotarget; 2016 May; 7(19):27975-87. PubMed ID: 27057625
[TBL] [Abstract][Full Text] [Related]
27. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
Narla G; DiFeo A; Fernandez Y; Dhanasekaran S; Huang F; Sangodkar J; Hod E; Leake D; Friedman SL; Hall SJ; Chinnaiyan AM; Gerald WL; Rubin MA; Martignetti JA
J Clin Invest; 2008 Aug; 118(8):2711-21. PubMed ID: 18596922
[TBL] [Abstract][Full Text] [Related]
28. Gain-of-function of mutant p53: mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells.
Ali A; Shah AS; Ahmad A
Cancer Lett; 2014 Nov; 354(1):87-96. PubMed ID: 25111898
[TBL] [Abstract][Full Text] [Related]
29. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
30. The
Ri K; Kim C; Pak C; Ri P; Om H
Microrna; 2020; 9(1):64-69. PubMed ID: 30868974
[TBL] [Abstract][Full Text] [Related]
31. DN-R175H p53 mutation is more effective than p53 interference in inducing epithelial disorganization and activation of proliferation signals in human carcinoma cells: role of E-cadherin.
Rieber M; Strasberg Rieber M
Int J Cancer; 2009 Oct; 125(7):1604-12. PubMed ID: 19507255
[TBL] [Abstract][Full Text] [Related]
32. p66α Suppresses Breast Cancer Cell Growth and Migration by Acting as Co-Activator of p53.
Zhang Q; Zhang Y; Zhang J; Zhang D; Li M; Yan H; Zhang H; Song L; Wang J; Hou Z; Yang Y; Zou X
Cells; 2021 Dec; 10(12):. PubMed ID: 34944103
[TBL] [Abstract][Full Text] [Related]
33. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
34. Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.
Chen M; Zhang H; Zhang G; Zhong A; Ma Q; Kai J; Tong Y; Xie S; Wang Y; Zheng H; Guo L; Lu R
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):74-82. PubMed ID: 30454896
[TBL] [Abstract][Full Text] [Related]
35. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis.
Subramanian M; Francis P; Bilke S; Li XL; Hara T; Lu X; Jones MF; Walker RL; Zhu Y; Pineda M; Lee C; Varanasi L; Yang Y; Martinez LA; Luo J; Ambs S; Sharma S; Wakefield LM; Meltzer PS; Lal A
Oncogene; 2015 Feb; 34(9):1094-104. PubMed ID: 24662829
[TBL] [Abstract][Full Text] [Related]
36. The Krüppel-like factor 6 represses proliferation and invasion of cutaneous malignant melanoma.
Li YY; Zheng QM; Zhang N; Zhang M
Pol J Pathol; 2023; 74(3):194-202. PubMed ID: 37955538
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.
Rubinstein M; Idelman G; Plymate SR; Narla G; Friedman SL; Werner H
Endocrinology; 2004 Aug; 145(8):3769-77. PubMed ID: 15131018
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of miR-181a in clear cell renal cell carcinoma is associated with lower KLF6 expression, enhanced cell proliferation, accelerated cell cycle transition, and diminished apoptosis.
Lei Z; Ma X; Li H; Zhang Y; Gao Y; Fan Y; Li X; Chen L; Xie Y; Chen J; Wu S; Tang L; Zhang X
Urol Oncol; 2018 Mar; 36(3):93.e23-93.e37. PubMed ID: 29066014
[TBL] [Abstract][Full Text] [Related]
39. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
40. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
